An orally available, small-molecule interferon inhibits viral replication

Citations Over TimeTop 12% of 2012 papers

Abstract

Most acute hepatitis C virus (HCV) infections become chronic and some progress to liver cirrhosis or hepatocellular carcinoma. Standard therapy involves an interferon (IFN)-α-based regimen, and efficacy of therapy has been significantly improved by the development of protease inhibitors. However, several issues remain concerning the injectable form and the side effects of IFN. Here, we report an orally available, small-molecule type I IFN receptor agonist that directly transduces the IFN signal cascade and stimulates antiviral gene expression. Like type I IFN, the small-molecule compound induces IFN-stimulated gene (ISG) expression for antiviral activity in vitro and in vivo in mice, and the ISG induction mechanism is attributed to a direct interaction between the compound and IFN-α receptor 2, a key molecule of IFN-signaling on the cell surface. Our study highlights the importance of an orally active IFN-like agent, both as a therapy for antiviral infections and as a potential IFN substitute.

Related Papers

• → Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice(2014)12 cited
• → Species- and agonist-dependent differences in the deactivation-kinetics of P2X 7 receptors(2001)32 cited
• → Being mindful of seven‐transmembrane receptor ‘guests’ when assessing agonist selectivity(2010)13 cited
• → An analysis of the functional interactions of selected contractile agonists in the guinea pig isolated trachea.(1988)7 cited
• → Up/Down: A New Method for Determining Agonist Properties(1994)